Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
A comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism
Neurobiology of Aging, Volume 35, No. 5, Year 2014
Notification
URL copied to clipboard!
Description
Parkinson disease is a progressive neurodegenerative disease for which leucine-rich repeat kinase 2 (LRRK2 carriers) p.G2019S confers substantial genotypic and population attributable risk. With informed consent, we have recruited clinical data from 778 patients from Tunisia (of which 266 have LRRK2 parkinsonism) and 580 unaffected subjects. Motor, autonomic, and cognitive assessments in idiopathic Parkinson disease and LRRK2 patients were compared with regression models. The age-associated cumulative incidence of LRRK2 parkinsonism was also estimated using case-control and family-based designs. LRRK2 parkinsonism patients had slightly less gastrointestinal dysfunction and rapid eye movement sleep disorder. Overall, disease penetrance in LRRK2 carriers was 80% by 70 years but women become affected a median 5 years younger than men. Idiopathic Parkinson disease patients with younger age at diagnosis have slower disease progression. However, age at diagnoses does not predict progression in LRRK2 parkinsonism. LRRK2 p.G2019S mutation is a useful aid to diagnosis and modifiers of disease in LRRK2 parkinsonism may aid in developing therapeutic targets. © 2014 Elsevier Inc.
Authors & Co-Authors
Trinh, Joanne
Canada, Vancouver
The University of British Columbia
Amouri, Rim
Tunisia, Tunis
Institut National de Neurologie Mongi-ben Hamida
Duda, John E.
United States, Philadelphia
University of Pennsylvania Perelman School of Medicine
Morley, James F.
United States, Philadelphia
University of Pennsylvania Perelman School of Medicine
Read, Matthew
United Kingdom, Basingstoke
Prn
Donald, Alan
Canada, Vancouver
The University of British Columbia
Vilarino-Guell, Carles
Canada, Vancouver
The University of British Columbia
Thompson, Christina
Canada, Vancouver
The University of British Columbia
Szu-Tu, Chelsea
Canada, Vancouver
The University of British Columbia
Gustavsson, Emil Karl
Canada, Vancouver
The University of British Columbia
Ben Sassi, Samia
Tunisia, Tunis
Institut National de Neurologie Mongi-ben Hamida
Hentati, Emna
Tunisia, Tunis
Institut National de Neurologie Mongi-ben Hamida
Zouari, Mourad
Tunisia, Tunis
Institut National de Neurologie Mongi-ben Hamida
Farhat, Emna
Tunisia, Tunis
Institut National de Neurologie Mongi-ben Hamida
Nabli, Fatma
Tunisia, Tunis
Institut National de Neurologie Mongi-ben Hamida
Hentati, F. F.
Tunisia, Tunis
Institut National de Neurologie Mongi-ben Hamida
Farrer, Matthew J.
Canada, Vancouver
The University of British Columbia
Statistics
Citations: 17
Authors: 17
Affiliations: 4
Identifiers
Doi:
10.1016/j.neurobiolaging.2013.11.015
e-ISSN:
15581497
Research Areas
Cancer
Health System And Policy
Study Design
Cross Sectional Study
Cohort Study
Case-Control Study
Study Locations
Tunisia
Participants Gender
Male
Female